In summer and fall 2017, NCATS issued 10 Therapeutic/Indication Pairing projects. The funded preclinical projects are serving as “use cases” to demonstrate the utility of an independent crowdsourcing effort or a computational algorithm to predict new therapeutic uses of an existing drug or biologic. View the projects below:
- Computational Repurposing of Chemotherapies for Pulmonary Hypertension
- Preclinical Evaluation of Vorinostat in Alopecia Areata
- Preclinical Testing of a Novel Therapeutic for Nonalcoholic Steatohepatitis
- Repurposing Pyronaridine as a Treatment for Chagas Disease
- Single-Cell-Driven Drug Repositioning Approaches to Target Inflammation in Atherosclerosis
- Impact of SAR152954 on Prenatal Alcohol Exposure-Induced Neurobehavioral Deficits
- An Endoplasmic Reticulum Calcium Stabilizer for the Treatment of Wolfram Syndrome
- Utilization of Phenotypic Precision Medicine to Identify Optimal Drug Combinations for the Treatment of Hepatocellular Carcinoma
- Targeting Glucose Metabolism for the Treatment of Hepatocellular Carcinoma
- Application of a Repurposed FDA Approved Drug as a Local Osteogenic Agent
University of Pittsburgh at Pittsburgh
Principal Investigator: Stephen Y. Chan, M.D., Ph.D., FAHA
Grant Number: 1-UH2-TR-002073-01
Project investigators will test a new mathematical algorithm to determine if specific combinations of chemotherapies ― drugs that have been tested for treatment of cancer ― are effective in treating pulmonary hypertension (PH). There are few effective medications for PH, a disease that affects the blood vessels in the lungs. If successful, this work could accelerate tests for two chemotherapies for individuals with PH and accelerate the development of new molecular inhibitors.
Columbia University Health Sciences
Principal Investigator: Angela M. Christiano, Ph.D.
Grant Number: 1-UH2-TR-002090-01
Alopecia areata (AA) is a common autoimmune form of hair loss that affects approximately six million people in the United States. The project team has performed genetic and gene expression studies in AA and identified a drug candidate to repurpose. They will evaluate the drug for preclinical efficacy in AA.
Icahn School of Medicine at Mount Sinai
Principal Investigator: Joel Thomas Dudley, Ph.D.
Grant Number: 1-UH2-TR-002077-01
Nonalcoholic steatohepatitis, or NASH, is a serious and growing health threat in the United States, affecting nearly 5 percent of the population. The goal of this project is to see if a drug with established safety information can be repurposed as a potential new treatment for NASH. If successful, the work could accelerate efforts to bring new therapies to the clinic for treatment of NASH.
Collaboration Pharmaceuticals, Inc.
Principal Investigators: Sean Ekins, Ph.D., D.Sc., Collaboration Pharmaceuticals, Inc.; Jair Lage de Siqueira Neto, Ph.D., University of California, San Diego; and Ester Cerdeira Sabino, M.D., Ph.D., University of Sao Paulo
Grant Number: 1-UH2-TR-002084-01
Approximately 6 to 7 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the cause of the deadly Chagas disease. Investigators on this project identified an antimalarial drug using computational Bayesian repurposing methods. The project team will test for the minimum effective dose to treat the acute model of this disease, while assessing the potential for combination therapy.
Icahn School of Medicine at Mount Sinai
Principal Investigator: Chiara Giannarelli, M.D., Ph.D.
Grant Number: 1-UH2-TR-002067-01
Atherosclerotic cardiovascular disease (CVD) is the leading cause of mortality and disability worldwide. Even in patients treated with the best standard-of-care programs, residual illness and death remain high. New strategies that directly target atherosclerosis—the main cause of CVD—are needed. This project may provide proof-of-concept evidence for the use of network-driven computational approaches to identify new therapies for atherosclerosis. Using quantitative non-invasive imaging as a translational platform for measuring drug efficacy in a preclinical setting could facilitate a smooth and fast translation of new therapeutics into clinical trials.
University of New Mexico Health Sciences Center
Principal Investigator: Daniel D. Savage, Ph.D.
Grant Number: 1-UH2-TR-002082-01
At least 2 to 4 percent of children born in the United States each year are at risk for having prenatal alcohol-associated brain damage, which can cause cognitive disabilities. This research project team will examine the effectiveness of a novel class of drugs for improving neurophysiologic and learning deficits in a well-established animal model of Fetal Alcohol Spectrum Disorder.
Washington University in St. Louis
Principal Investigator: Fumihiko Urano, M.D., Ph.D.
Grant Number: 1-UH2-TR-002065-01
Endoplasmic reticulum (ER) is an emerging target for human chronic diseases, especially in diabetes and neurodegeneration. Wolfram syndrome is a rare autosomal recessive genetic disorder characterized by juvenile-onset diabetes and neurodegeneration; it is considered a prototype of ER disorder. This project may lead to a breakthrough for treatments of such common diseases as diabetes, neurodegeneration and blindness.
Utilization of Phenotypic Precision Medicine to Identify Optimal Drug Combinations for the Treatment of Hepatocellular Carcinoma
University of Florida
Principal Investigators: Ali Zarrinpar, M.D., Ph.D., University of Florida; and Dean Ho, M.S., Ph.D., University of California, Los Angeles
Grant Number: 1-UH2-TR-002087-01
This project applies a computational platform (Phenotypic Precision Medicine) to optimize combination therapy for the treatment of liver cancer. Project researchers will demonstrate the ability to devise novel combination therapies and then plan a clinical trial to test the feasibility and efficacy of this approach to treat liver cancer.
University of California, San Francisco
Principal Investigator: Bin Chen, Ph.D.
Grant Number: 1-R21-TR-001743-01
Hepatocellular carcinoma is the third leading cause of cancer-related death globally, and effective treatments are limited. This project will use the recent public molecular datasets to predict drugs for hepatocellular carcinoma and evaluate them using thorough preclinical models.
Principal Investigators: Nick J. Willett, Ph.D., and Sreedhara Sangadala, Ph.D.
Grant Number: 1-R21-TR-001751-01
This project will investigate the potential of a family of Food and Drug Administration-approved small molecules to be repurposed as a therapeutic strategy to induce bone formation for spine fusion.